NASDAQ: INDV

Indivior Pharmaceuticals (INDV) Stock Analysis & Forecast

Nov 9 close

$27.62+1.46 (+5.6%)

Gekko Brief

AI summaryNov 5 close

Indivior's week centers on its completed merger with Supernus Pharmaceuticals, with the combined entity now trading under the Supernus name and ticker SUPN effective 3 November. Jack A. Khattar was appointed CEO and director, with four existing officers and four directors departing. This follows strong third-quarter results reported 29 October, with net revenue climbing 13% to $356 million, net income rising to $137 million from $42 million, and EPS of $1.32 topping estimates by $0.52; the company also issued FY2026 guidance projecting revenue between $1.29 billion and $1.36 billion.

The stock closed at $26.74, down 5.2%, sitting below both its 50-day average of $34.69 and 200-day average of $35.61, with the 50-day below the 200-day. Despite this technical headwind, the GekkoIndex sits at 90, placing it in the Buying zone, and the price is 29.2% below Gekko Fair Value of $37.75.

No further earnings are scheduled until 25 February 2027, keeping that catalyst outside a typical 20-trading-day hold. Smart money activity over the last 90 days includes one open-market insider purchase, alongside one billionaire holder and one trailblazer holder. Analyst coverage from 2 firms shows both rated buy, with a consensus target of $49.50. Seasonality over the next 20 trading days has averaged a 3% return across 4 years, though gains occurred in only 2 of those years.

Written by AI from the Nov 5, 2026 close and checked automatically against the figures on this page.

Indivior Pharmaceuticals price vs fair value

$37.75$27.62Nov ’25May ’26Nov ’26
Close $27.62200-day averageGekko Fair Value $37.75

Indivior Pharmaceuticals quick facts

Market cap
$4.53B
P/E ratio
10.2
Forward P/E
9.4
EPS, TTM
$3.57
Revenue, TTM
$1.37B
Profit margin
32.8%
Dividend yield
0.00%
Beta
1.13
Volume
4.20M avg 3.59M
1-year return
−13.3%
Typical daily move
±7%
Typical 20-day move
±9.6%
50-day average
$34.36
200-day average
$35.54
Next earnings
Feb 25 before open
Shares outstanding
118.0M
52-week range
$25.92$42.81

Indivior Pharmaceuticals swing-trade checklist

Indivior Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive0 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $27.62 is below the 50-day ($34.36) and 200-day ($35.54) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    82.7, Buying

    Reading 82.7 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    26.8% below

    Price is 26.8% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 1 open-market insider purchase.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +10.5% on average

    From this point in the calendar, the next 20 trading days averaged +10.5% over 4 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Indivior Pharmaceuticals stock chart and price history

Indivior Pharmaceuticals closed at $27.62 on Nov 9, 2026, −13.3% over the past year, inside a 52-week range of $25.92 to $42.81.

Close50-day average200-day averageVolume
Indivior Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$15$20$25$30$35$40DecJan 2026FebMarAprMayJunJulAugSepOctNov27.62

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−22.9%
3 months
−28.1%
6 months
−28.9%
1 year
−13.3%
The full INDV chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open INDV in Gekko

Follow Indivior Pharmaceuticals through every session

Put INDV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track INDV in GekkoFree for 7 days. No credit card required.

About Indivior Pharmaceuticals

Indivior Pharmaceuticals develops, manufactures, and distributes buprenorphine-based medicines used in treating opioid dependence. Its lineup of prescription pharmaceuticals includes Suboxone Film, Suboxone Tablet, and Subutex Tablet, products aimed at patients managing opioid use disorder. These medicines represent the core of what the company is known for within its field of prescription treatment.

Indivior Pharmaceuticals is structured as a holding company overseeing the research, production, and distribution activities tied to these medications. It organizes its operations across distinct geographic segments, namely the United States, the United Kingdom, and a broader international market that spans other regions where its products reach patients and healthcare providers.

The company was established on September 26, 2014, and its corporate headquarters are situated in North Chesterfield, Virginia. Its shares are listed on the NASDAQ under the ticker INDV, allowing investors to trade ownership in the business through that exchange.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
indivior.com

Indivior Pharmaceuticals GekkoIndex: the smart money zone

Indivior Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 82.7, in the Buying zone, up 29.9 points over five sessions.

010082.7Buying

Up 29.9 points over five sessions, from the Neutral zone.

Reading for Nov 9, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)55+2.7%+4.9%+7.3%+8.8%
Accumulation194−0.2%−1.1%−2.7%+2.3%
Neutral363+0.8%+2.2%+5.3%+10.6%
Distribution80+2.6%+3.6%+5.8%+13.8%
Selling6Too few readings yet

Average INDV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the INDV price, zone by zone.Track INDV in Gekko

Is Indivior Pharmaceuticals stock overvalued? Gekko Fair Value

Indivior Pharmaceuticals trades 26.8% below Gekko Fair Value of $37.75, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Indivior Pharmaceuticals shares are worth, recalculated every trading day.

$37.75

Gekko Fair Value, Nov 6, 2026

26.8% Undervalued

At the end of Aug 2026 the price was 23.4% below the estimate.

Gekko Fair ValueShare price, month end
$38$36Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open INDV in Gekko

Indivior Pharmaceuticals insider and Congress trading

Insiders filed 1 open-market purchase in Indivior Pharmaceuticals worth $54K, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$54Kin 1 open-market purchase

FiledInsiderTypeSharesValue
Aug 27Anderson Woodrow D
officer: Chief Accounting Officer
Purchase1,500$54K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in INDV were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for INDV, plotted on the chart in Gekko.Open INDV in Gekko

Buybacks

Indivior Pharmaceuticals has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$462K
As a share of market cap
0.01%
Trailing four quarters
$302.7M

From company filings.

Hedge funds and billionaires quarter ended Jun 30

2of the funds Gekko tracks hold INDV.

0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Indivior Pharmaceuticals earnings: next date and track record

Indivior Pharmaceuticals reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±13.2%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−22.5%Feb ’25+22.3%Apr ’25+21.0%Jul ’25+16.4%Oct ’25−2.7%Feb ’26+10.3%Apr ’26−8.8%Aug ’26+1.7%Oct ’26
ReportedEPSSurpriseRevenueSurpriseMove
Oct 29, 2026$1.32
est $1.06
+24.5%$356.0M
est $329.4M
+8.1%+1.7%
Aug 3, 2026$1.15
est $0.97
+18.6%$343.0M
est $306.2M
+12.0%−8.8%
Apr 30, 2026$0.96
est $0.66
+45.5%$317.0M
est $272.8M
+16.2%+10.3%
Feb 26, 2026$0.82
est $0.65
+26.2%$358.0M
est $305.6M
+17.1%−2.7%
Oct 30, 2025$0.72
est $0.38
+89.5%$314.0M
est $306.2M
+2.5%+16.4%
Jul 31, 2025$0.51
est $0.26
+96.2%$302.0M
est $255.2M
+18.3%+21.0%
Apr 24, 2025$0.41
est $0.22
+86.4%$266.0M
est $242.3M
+9.8%+22.3%
Feb 20, 2025$0.32
est $0.32
0.0%$299.0M
est $240.1M
+24.5%−22.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Indivior Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Indivior Pharmaceuticals is $49.50, +79.2% from the last close, from 2 firms rating the stock in the last 90 days.

$49.50consensus 12-month target, +79.2% from the last close
Buy2
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 2 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 28BarclaysBuy, maintained$45+62.9%
Sep 17Craig-HallumBuy, maintained——
+7.3%average 20-day move after past Buying readings
+10.5%average move over the next 20 trading days in the last 4 years
±7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Indivior Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Indivior Pharmaceuticals averaged +10.5% across the last 4 years, rising in 3 of them.

Next 20 trading days, by year

+28.1%2021−14.9%2023+14.0%2024+15.5%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.1%2 of 4
Next 10 trading days+6.5%3 of 4
Next 15 trading days+3.2%2 of 4
Next 20 trading days+10.5%3 of 4
Next 30 trading days+11.3%3 of 4

For scale, INDV’s typical 20-trading-day move in either direction is about 9.6%.

Indivior Pharmaceuticals market cap and key statistics

Indivior Pharmaceuticals’s market cap is $4.53B, with a P/E ratio of 10.2 and revenue of $1.37B over the last twelve months.

Valuation

Market cap
$4.53B
P/E ratio
10.2
Forward P/E
9.4
EPS, TTM
$3.57
Gekko Fair Value
$37.75

Trading

Volume
4.20M
Avg volume, 20 days
3.59M
52-week high
$42.81
52-week low
$25.92
Shares outstanding
118.0M

Financials

Revenue, TTM
$1.37B
Profit margin
32.8%
Return on equity
12.2%
Quarterly earnings growth, YoY
+239.4%

Risk and income

Beta
1.13
Typical daily move
±7%
Typical 20-day move
±9.6%
Dividend yield
0.00%

Indivior Pharmaceuticals stock news this week

3 headlines about Indivior Pharmaceuticals from the past week, newest first, each linking to the publisher.

Indivior Pharmaceuticals peers

Indivior Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Indivior Pharmaceuticals stock FAQ

What is Indivior Pharmaceuticals’s market cap?

Indivior Pharmaceuticals’s market cap is $4.53B at the Nov 9, 2026 close of $27.62, with 118.0M shares outstanding. The shares trade on a P/E ratio of 10.2.

What is the Indivior Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Indivior Pharmaceuticals is $49.50, +79.2% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Indivior Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Indivior Pharmaceuticals is undervalued: the Nov 9, 2026 close of $27.62 is 26.8% below Gekko Fair Value of $37.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Indivior Pharmaceuticals report earnings next?

Indivior Pharmaceuticals is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $0.99 per share on revenue of $337.9M. Indivior Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 13.2% on average across the report.

What is Indivior Pharmaceuticals’s 52-week high and low?

Indivior Pharmaceuticals’s 52-week high is $42.81 and its 52-week low is $25.92; it closed at $27.62 on Nov 9, 2026, −13.3% over the past year.

Is Indivior Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Indivior Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.